Sanjay Babu Katiyar

Central Drug Research Institute, Lucknow, Uttar Pradesh, India

Are you Sanjay Babu Katiyar?

Claim your profile

Publications (10)19.22 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of tetrahydro-beta-carbolines and 1,3,5-triazine hybrids have been synthesized and evaluated for their cytotoxicity against a panel of eight human cancer cell lines and normal human fibroblasts (NIH3T3). It led us to discovery of racemic compounds 69, 71 and 75, which are selectively cytotoxic towards KB (oral cancer) cell line with IC50 values of 105.8, 664.7 and 122.2 nM, respectively; while their enantiopure forms are less active and not selective. Enantiopure compound 42 showed 2.5 times more selectivity towards MCF7 cells over normal fibroblast NIH3T3 cells with an IC50 value of 740 nM, also arrests cell cycle in G1 phase and induces apoptosis in MCF7 and MDA MB231 cell lines.
    European Journal of Medicinal Chemistry 02/2010; 45(6):2265-76. · 3.43 Impact Factor
  • Sanjay Babu Katiyar, Arun Kumar, Prem M. S. Chauhan
    [Show abstract] [Hide abstract]
    ABSTRACT: ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
    ChemInform 01/2007; 38(11).
  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of 2,4,6 trisubstituted pyrimidines and triazines have been synthesized and screened for its in vitro antileishmanial activity profile in promastigote model. Nine compounds have shown > 94% inhibition against promastigotes at a concentration of 10 microg/mL.
    Bioorganic & Medicinal Chemistry 12/2006; 14(23):7706-15. · 2.90 Impact Factor
  • Sanjay Babu Katiyar, Arun Kumar, Prem M. S. Chauhan
    [Show abstract] [Hide abstract]
    ABSTRACT: Pyrazolopyrimidine and pyrimidopyrimidine derivatives have shown a wide range of biological activities such as acting as A1 adenosine receptors, kinase insert domain receptor (KDR), Rous sarcoma oncogene (Src), epidermal growth factor receptor (EGFR), antiproliferative, dihydrofolate reductase (DHFR), antimicrobial, antifungal, and lipid peroxidation. Because of this wide range of activities, we have synthesized pyrazolo[3,4‐d]pyrimidines and pyrimido[4,5‐d]pyrimidin‐4‐one derivatives.
    Synthetic Communications 10/2006; 36(20):2963-2973. · 1.06 Impact Factor
  • Arun Kumar, Sanjay Babu Katiyar, Suman Gupta, Prem M S Chauhan
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of triazino tetrahydroisoquinolines (3-5) and beta-carboline derivatives (15-27) have been synthesized as novel antileishmanial agents. Among them, compounds 15, 16 and 25 have shown 78.0%, 78.6% and 68.0% in vivo inhibition against Leishmania donovani at a dose of 50 mg kg(-1) x 5 days, respectively, while compounds 3 and 18 exhibited 55.6% and 53.3% in vivo inhibitions, respectively, against L. donovani at a dose of 50 mg kg(-1) x 5 days.
    European Journal of Medicinal Chemistry 02/2006; 41(1):106-13. · 3.43 Impact Factor
  • A KUMAR, S KATIYAR, S GUPTA, P CHAUHAN
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of triazino tetrahydroisoquinolines (3–5) and β-carboline derivatives (15–27) have been synthesized as novel antileishmanial agents. Among them, compounds 15, 16 and 25 have shown 78.0%, 78.6% and 68.0% in vivo inhibition against Leishmania donovani at a dose of 50 mg kg–1 × 5 days, respectively, while compounds 3 and 18 exhibited 55.6% and 53.3% in vivo inhibitions, respectively, against L. donovani at a dose of 50 mg kg–1 × 5 days.
    European Journal of Medicinal Chemistry - EUR J MED CHEM. 01/2006; 41(1):106-113.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of 22 compounds were synthesized and screened against Plasmodium falciparum NF-54 strain. Of the screened compounds, 6 compounds showed MIC in the range between 1 and 2 microg/mL. These compounds are 32 times more potent than the cycloguanil which was used as the standard drug.
    Bioorganic & Medicinal Chemistry Letters 12/2005; 15(22):4957-60. · 2.34 Impact Factor
  • Sanjay Babu Katiyar, Iti Bansal, J K Saxena, P M S Chauhan
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of 21 compounds of trisubstituted pyrimidine derivatives have been synthesized and evaluated for their in vitro topoisomerase II inhibitory activity against filarial parasite Setaria cervi. Out of these, seven compounds (8, 11-14, 25 and 28) have shown 60-80% inhibition at 40 and 20 microg/mL concentration. Five compounds (12, 13, 14, 25 and 28) exhibited 70-80% inhibition at 10 microg/mL concentration and three compounds (13, 14 and 28) have shown 40-60% inhibition at 5 microg/mL concentration. All the above mentioned compounds have shown better topo II inhibitory activity than standard antifilarial drug (DEC) and enzyme topo II inhibitors (Novobiocin, Nalidixic acid).
    Bioorganic & Medicinal Chemistry Letters 02/2005; 15(1):47-50. · 2.34 Impact Factor
  • Arun Kumar, Sanjay Babu Katiyar, Anu Agarwal, P M S Chauhan
    [Show abstract] [Hide abstract]
    ABSTRACT: Antimalarial chemotherapy has become more complex and challenging because of multidrug resistant strains of Plasmodium falciparum. Due to resistance of malarial parasite against well known drugs, the chemotherapy of malaria has become complicated. In this review we have discussed brief introduction followed by life cycle of malaria parasite. The list of commercially available antimalarial drugs along with there action on different stages of parasite have been discussed. A brief description of their mechanism of action and advantages and disadvantages were reported. The natural products as antimalarial have been discussed in the review. On the basis of chemical classes the natural products were divided in the following categories; Quinoline alkaloids, Iso-quinoline alkaloids, Indoloquinoline alkaloids, Carbolines, Bis-isoquinoline, 4-Quinazole derivatives, Trioxanes, Terpenes, Naphthoquinone, Anthraquinones, Chalcones, Hydroxy flavanones, Coumarins and phenolic glycoside. The combination chemotherapy has been highlighted in the review. The Biochemical and Immunological changes in malarial infection are discussed along with complications of malarial chemotherapy due to resistance. In the conclusion section, the future strategies for the chemotherapy of malaria have been discussed.
    Current Medicinal Chemistry 08/2003; 10(13):1137-50. · 3.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malaria is a tropical disease caused by the genus Plasmodium. The sexual stage of the plasmodium is carried by mosquito while the asexual stage is carried by man. Transmission from the mosquito to man is through mosquito bite. Commonly presented symptoms of malarial attack include fever, weakness, anorexia, and anaemia. Some complications such as convulsion (in children) and acute pulmonary edema are common. The conventional drugs used in malarial chemotherapy include, chloroquin, sulfadoxine/pyramethamine, quinine and primaquine. Newer drugs in use include artemisine and its derivatives (such as dihydroartemisinine, artesunate, artemether), halofantrine, atovaquine, malaria vaccines, and artemisinine combinations (such as artemether/lumenfantrine, artesunate/mefloquine). These newer drugs were developed based on some shortcomings of the conventional drugs such as drug resistance and unbearable side effects. Of all the drugs available for the first line treatment of malaria, the artemisinine combinations are the drugs of choice as they possess reduced recrudescence and relapse when given for 3 days. Some new combinations are still on trial and include fosmidomycin/clindamycin. Malaria vaccines which show some promising features are also still undergoing more trials.
    Drugs of The Future - DRUG FUTURE. 01/2003; 28(3).